Low-Volume Aldosterone Immunoassay Validated for Small Samples
By LabMedica International staff writers Posted on 26 Sep 2017 |
Image: The infinite F50 absorbance reader (Photo courtesy of Tecan).
Heart failure is a severe cardiovascular disease in adults and children and is characterized by structural or functional abnormalities of the heart. Heart failure leads to an inappropriate blood circulation and subsequently to an undersupply of metabolizing tissues with oxygen and nutrients.
The humoral parameter aldosterone is part of the renin-angiotensin-aldosterone system (RAAS), which plays a major role in the body's salt and water balance. In clinical settings, serum aldosterone is recommended as a screening and diagnosis parameter for primary aldosteronism in high-risk patients.
Scientists at the Heinrich-Heine-University Düsseldorf (Germany) developed and validated a bioanalytical assay for the determination of aldosterone concentrations in small sample volumes. An immunoassay was developed based on a commercially available aldosterone enzyme-linked immunosorbent assay (ELISA) kit. Serum samples were donated by healthy volunteers. The optical density was measured using the absorbance reader infinite F50.
The investigators reported that the assay with a range 31.3 pg/mL to 1,000 pg/mL (86.9 pmol/L to 2,775 pmol/L) was characterized by a between-run accuracy from − 3.8% to − 0.8% and a between-run imprecision ranging from 4.9% to 8.9% (coefficient of variation). For within-run accuracy, the relative error was between − 11.1% and + 9.0%, while within-run imprecision ranged from 1.2% to 11.8% (CV). For parallelism and dilutional linearity, the relative error of back-calculated concentrations varied from − 14.1% to + 8.4% and from − 7.4% to + 10.5%, respectively. No impact of hemolysis on accurate sample determinations was observed.
The authors concluded that their present immunoassay is compliant with current bioanalytical guidelines of the European Medicines Agency (EMA) and allows accurate and precise aldosterone determinations in 40 µL serum. As the assay runs with low-volume samples, it is especially valuable for pediatric investigations, but is not limited to this population. The study was published originally published online on July 27, 2017, in the journal Practical Laboratory Medicine.
Related Links:
Heinrich-Heine-University Düsseldorf
The humoral parameter aldosterone is part of the renin-angiotensin-aldosterone system (RAAS), which plays a major role in the body's salt and water balance. In clinical settings, serum aldosterone is recommended as a screening and diagnosis parameter for primary aldosteronism in high-risk patients.
Scientists at the Heinrich-Heine-University Düsseldorf (Germany) developed and validated a bioanalytical assay for the determination of aldosterone concentrations in small sample volumes. An immunoassay was developed based on a commercially available aldosterone enzyme-linked immunosorbent assay (ELISA) kit. Serum samples were donated by healthy volunteers. The optical density was measured using the absorbance reader infinite F50.
The investigators reported that the assay with a range 31.3 pg/mL to 1,000 pg/mL (86.9 pmol/L to 2,775 pmol/L) was characterized by a between-run accuracy from − 3.8% to − 0.8% and a between-run imprecision ranging from 4.9% to 8.9% (coefficient of variation). For within-run accuracy, the relative error was between − 11.1% and + 9.0%, while within-run imprecision ranged from 1.2% to 11.8% (CV). For parallelism and dilutional linearity, the relative error of back-calculated concentrations varied from − 14.1% to + 8.4% and from − 7.4% to + 10.5%, respectively. No impact of hemolysis on accurate sample determinations was observed.
The authors concluded that their present immunoassay is compliant with current bioanalytical guidelines of the European Medicines Agency (EMA) and allows accurate and precise aldosterone determinations in 40 µL serum. As the assay runs with low-volume samples, it is especially valuable for pediatric investigations, but is not limited to this population. The study was published originally published online on July 27, 2017, in the journal Practical Laboratory Medicine.
Related Links:
Heinrich-Heine-University Düsseldorf
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines